Therapies with broad yet targeted clinical utility
At Ayala, our work maps back to one underlying goal: Develop and commercialize therapies that improve treatment outcomes for people living with rare tumors and aggressive cancers.
By building a pipeline of gamma secretase inhibitors (GSIs) with broad yet targeted clinical utility, we aim to serve patient populations in need of better therapies. Our investigational product candidates have been, and are currently still being, evaluated in clinical trials at leading oncology centers across the United States, Europe and Canada.
If Novartis exercises its option to license AL102 for the treatment of MM, Ayala will be entitled to receive from Novartis an exercise fee and certain development, regulatory and commercial milestone payments as well as tiered royalties on net sales of licensed products
R/M ACC = Recurring / Metastatic Adenoid Cystic Carcinoma
R/R T-ALL = Relapsed / Refractory T-cell Acute Lymphoblastic Leukemia
R/R MM = Relapsed / Refractory Multiple Myeloma
BCMA = B-cell Maturation Antigen
Using our deep understanding of the Notch pathway, we develop precise therapies to address the underlying key drivers of tumor growth in patients where GSI inhibition of Notch can lead to clinical benefit.